Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer

Francesca Moretti, Paola D'Antona, Emanuele Finardi, Marco Barbetta, Lorenzo Dominioni, Albino Poli, Elisabetta Gini, Douglas M. Noonan, Andrea Imperatori, Nicola Rotolo, Maria Cattoni, Paola Campomenosi

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Selected circulating microRNAs (miRNAs) have been suggested for non-invasive screening of non-small cell lung cancer (NSCLC), however the numerous proposed miRNA signatures are inconsistent. Aiming to identify miRNAs suitable specifically for stage I-II NSCLC screening in serum/plasma samples, we searched the databases "Pubmed", "Medline", "Scopus", "Embase" and "WOS" and systematically reviewed the publications reporting quantitative data on the efficacy [sensitivity, specificity and/or area under the curve (AUC)] of circulating miRNAs as biomarkers of NSCLC stage I and/or II. The 20 studies fulfilling the search criteria included 1110 NSCLC patients and 1009 controls, and were of medium quality according to Quality Assessment of Diagnostic Accuracy Studies checklist. In these studies, the patient cohorts as well as the control groups were heterogeneous for demographics and clinicopathological characteristics; moreover, numerous pre-analytical and analytical variables likely influenced miRNA determinations, and potential bias of hemolysis was often underestimated. We identified four circulating miRNAs scarcely influenced by hemolysis, each featuring high sensitivity ( > 80%) and AUC ( > 0.80) as biomarkers of stage I-II NSCLC: miR- 223, miR-20a, miR-448 and miR-145; four other miRNAs showed high specificity ( > 90%): miR-628-3p, miR-29c, miR-210 and miR-1244. In a model of two-step screening for stage I-II NSCLC using first the above panel of serum miRNAs with high sensitivity and high AUC, and subsequently the panel with high specificity, the estimated overall sensitivity is 91.6% and overall specificity is 93.4%. These and other circulating miRNAs suggested for stage I-II NSCLC screening require validation in multiple independent studies before they can be proposed for clinical application.

Original languageEnglish
Pages (from-to)94980-94996
Number of pages17
JournalOncotarget
Volume8
Issue number55
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

MicroRNAs
Non-Small Cell Lung Carcinoma
Biomarkers
Area Under Curve
Hemolysis
Early Detection of Cancer
Checklist
Serum
PubMed
Publications
Cohort Studies
Research Design
Demography
Databases
Sensitivity and Specificity
Control Groups

Keywords

  • Biomarkers
  • Circulating
  • MicroRNA
  • Non-small cell lung cancer
  • Stage I-II NSCLC

ASJC Scopus subject areas

  • Oncology

Cite this

Moretti, F., D'Antona, P., Finardi, E., Barbetta, M., Dominioni, L., Poli, A., ... Campomenosi, P. (2017). Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer. Oncotarget, 8(55), 94980-94996. https://doi.org/10.18632/oncotarget.21739

Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer. / Moretti, Francesca; D'Antona, Paola; Finardi, Emanuele; Barbetta, Marco; Dominioni, Lorenzo; Poli, Albino; Gini, Elisabetta; Noonan, Douglas M.; Imperatori, Andrea; Rotolo, Nicola; Cattoni, Maria; Campomenosi, Paola.

In: Oncotarget, Vol. 8, No. 55, 01.11.2017, p. 94980-94996.

Research output: Contribution to journalReview article

Moretti, F, D'Antona, P, Finardi, E, Barbetta, M, Dominioni, L, Poli, A, Gini, E, Noonan, DM, Imperatori, A, Rotolo, N, Cattoni, M & Campomenosi, P 2017, 'Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer', Oncotarget, vol. 8, no. 55, pp. 94980-94996. https://doi.org/10.18632/oncotarget.21739
Moretti F, D'Antona P, Finardi E, Barbetta M, Dominioni L, Poli A et al. Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer. Oncotarget. 2017 Nov 1;8(55):94980-94996. https://doi.org/10.18632/oncotarget.21739
Moretti, Francesca ; D'Antona, Paola ; Finardi, Emanuele ; Barbetta, Marco ; Dominioni, Lorenzo ; Poli, Albino ; Gini, Elisabetta ; Noonan, Douglas M. ; Imperatori, Andrea ; Rotolo, Nicola ; Cattoni, Maria ; Campomenosi, Paola. / Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer. In: Oncotarget. 2017 ; Vol. 8, No. 55. pp. 94980-94996.
@article{5b170be056fa4127a58c3b9684fa102e,
title = "Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer",
abstract = "Selected circulating microRNAs (miRNAs) have been suggested for non-invasive screening of non-small cell lung cancer (NSCLC), however the numerous proposed miRNA signatures are inconsistent. Aiming to identify miRNAs suitable specifically for stage I-II NSCLC screening in serum/plasma samples, we searched the databases {"}Pubmed{"}, {"}Medline{"}, {"}Scopus{"}, {"}Embase{"} and {"}WOS{"} and systematically reviewed the publications reporting quantitative data on the efficacy [sensitivity, specificity and/or area under the curve (AUC)] of circulating miRNAs as biomarkers of NSCLC stage I and/or II. The 20 studies fulfilling the search criteria included 1110 NSCLC patients and 1009 controls, and were of medium quality according to Quality Assessment of Diagnostic Accuracy Studies checklist. In these studies, the patient cohorts as well as the control groups were heterogeneous for demographics and clinicopathological characteristics; moreover, numerous pre-analytical and analytical variables likely influenced miRNA determinations, and potential bias of hemolysis was often underestimated. We identified four circulating miRNAs scarcely influenced by hemolysis, each featuring high sensitivity ( > 80{\%}) and AUC ( > 0.80) as biomarkers of stage I-II NSCLC: miR- 223, miR-20a, miR-448 and miR-145; four other miRNAs showed high specificity ( > 90{\%}): miR-628-3p, miR-29c, miR-210 and miR-1244. In a model of two-step screening for stage I-II NSCLC using first the above panel of serum miRNAs with high sensitivity and high AUC, and subsequently the panel with high specificity, the estimated overall sensitivity is 91.6{\%} and overall specificity is 93.4{\%}. These and other circulating miRNAs suggested for stage I-II NSCLC screening require validation in multiple independent studies before they can be proposed for clinical application.",
keywords = "Biomarkers, Circulating, MicroRNA, Non-small cell lung cancer, Stage I-II NSCLC",
author = "Francesca Moretti and Paola D'Antona and Emanuele Finardi and Marco Barbetta and Lorenzo Dominioni and Albino Poli and Elisabetta Gini and Noonan, {Douglas M.} and Andrea Imperatori and Nicola Rotolo and Maria Cattoni and Paola Campomenosi",
year = "2017",
month = "11",
day = "1",
doi = "10.18632/oncotarget.21739",
language = "English",
volume = "8",
pages = "94980--94996",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "55",

}

TY - JOUR

T1 - Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer

AU - Moretti, Francesca

AU - D'Antona, Paola

AU - Finardi, Emanuele

AU - Barbetta, Marco

AU - Dominioni, Lorenzo

AU - Poli, Albino

AU - Gini, Elisabetta

AU - Noonan, Douglas M.

AU - Imperatori, Andrea

AU - Rotolo, Nicola

AU - Cattoni, Maria

AU - Campomenosi, Paola

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Selected circulating microRNAs (miRNAs) have been suggested for non-invasive screening of non-small cell lung cancer (NSCLC), however the numerous proposed miRNA signatures are inconsistent. Aiming to identify miRNAs suitable specifically for stage I-II NSCLC screening in serum/plasma samples, we searched the databases "Pubmed", "Medline", "Scopus", "Embase" and "WOS" and systematically reviewed the publications reporting quantitative data on the efficacy [sensitivity, specificity and/or area under the curve (AUC)] of circulating miRNAs as biomarkers of NSCLC stage I and/or II. The 20 studies fulfilling the search criteria included 1110 NSCLC patients and 1009 controls, and were of medium quality according to Quality Assessment of Diagnostic Accuracy Studies checklist. In these studies, the patient cohorts as well as the control groups were heterogeneous for demographics and clinicopathological characteristics; moreover, numerous pre-analytical and analytical variables likely influenced miRNA determinations, and potential bias of hemolysis was often underestimated. We identified four circulating miRNAs scarcely influenced by hemolysis, each featuring high sensitivity ( > 80%) and AUC ( > 0.80) as biomarkers of stage I-II NSCLC: miR- 223, miR-20a, miR-448 and miR-145; four other miRNAs showed high specificity ( > 90%): miR-628-3p, miR-29c, miR-210 and miR-1244. In a model of two-step screening for stage I-II NSCLC using first the above panel of serum miRNAs with high sensitivity and high AUC, and subsequently the panel with high specificity, the estimated overall sensitivity is 91.6% and overall specificity is 93.4%. These and other circulating miRNAs suggested for stage I-II NSCLC screening require validation in multiple independent studies before they can be proposed for clinical application.

AB - Selected circulating microRNAs (miRNAs) have been suggested for non-invasive screening of non-small cell lung cancer (NSCLC), however the numerous proposed miRNA signatures are inconsistent. Aiming to identify miRNAs suitable specifically for stage I-II NSCLC screening in serum/plasma samples, we searched the databases "Pubmed", "Medline", "Scopus", "Embase" and "WOS" and systematically reviewed the publications reporting quantitative data on the efficacy [sensitivity, specificity and/or area under the curve (AUC)] of circulating miRNAs as biomarkers of NSCLC stage I and/or II. The 20 studies fulfilling the search criteria included 1110 NSCLC patients and 1009 controls, and were of medium quality according to Quality Assessment of Diagnostic Accuracy Studies checklist. In these studies, the patient cohorts as well as the control groups were heterogeneous for demographics and clinicopathological characteristics; moreover, numerous pre-analytical and analytical variables likely influenced miRNA determinations, and potential bias of hemolysis was often underestimated. We identified four circulating miRNAs scarcely influenced by hemolysis, each featuring high sensitivity ( > 80%) and AUC ( > 0.80) as biomarkers of stage I-II NSCLC: miR- 223, miR-20a, miR-448 and miR-145; four other miRNAs showed high specificity ( > 90%): miR-628-3p, miR-29c, miR-210 and miR-1244. In a model of two-step screening for stage I-II NSCLC using first the above panel of serum miRNAs with high sensitivity and high AUC, and subsequently the panel with high specificity, the estimated overall sensitivity is 91.6% and overall specificity is 93.4%. These and other circulating miRNAs suggested for stage I-II NSCLC screening require validation in multiple independent studies before they can be proposed for clinical application.

KW - Biomarkers

KW - Circulating

KW - MicroRNA

KW - Non-small cell lung cancer

KW - Stage I-II NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85032946824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032946824&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21739

DO - 10.18632/oncotarget.21739

M3 - Review article

VL - 8

SP - 94980

EP - 94996

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 55

ER -